CM
BMRN icon

Crestline Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Crestline Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-22,592
Closed -$2.05M – 130
2017
Q2 		$2.05M Sell
22,592
-2,207
-9% -$201K 0.27% 40
2017
Q1 		$2.18M Buy
24,799
+17,106
+222% +$1.52M 0.4% 27
2016
Q4 		$637K Buy
7,693
+3,051
+66% +$262K 0.16% 46
2016
Q3 		$429K Buy
+4,642
New +$437K 0.05% 155

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Crestline Management's BMRN Position: Q3 2017 in Review

Crestline Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2017, closing a stake of 22,592 shares — an estimated $2.05M sold.

Crestline Management first reported a position in BMRN in Q3 2016 and held it in 4 quarters. The position peaked at $2.18M in Q1 2017. 411 funds tracked by Wall St. Rank hold BMRN as of Q3 2017.

  • Crestline Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Crestline Management sold 22,592 BioMarin Pharmaceuticals shares in Q3 2017, an estimated $2.05M.
  • Crestline Management first reported a position in BioMarin Pharmaceuticals in Q3 2016 and held it in 4 quarters.
  • Crestline Management's BioMarin Pharmaceuticals position peaked at $2.18M in Q1 2017.
  • 411 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2017.

Based on Crestline Management's 13F filing for Q3 2017, filed 14 Nov 2017.